Amid a deluge of demand for cell culture media, Thermo Fisher Scientific has tied a ribbon on a $76 million investment to stand up spare capacity. The company has completed an expansion at its dry powder media manufacturing plant in Grand Island, New York, creating “redundant capacity” and expanding the site’s production arsenal to include technology and materials used in the development and commercial production of new vaccines and biologic drugs, Source: Fierce Pharma 4/8/2022